Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia

Effects of Fish Oil Supplementation on Vascular Structure and Function in Hypertensive Patients With Hypertriglyceridemia

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01480687

Enrollment

Registered

2011-11-29

Start date

2011-05-31

Completion date

2012-12-31

Last updated

2011-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Hypertriglyceridemia

Keywords

Hypertension, Endothelial dysfunction, Vascular stiffness

Brief summary

The objective of this study is to compare the effects of ciprofibrate versus omega-3 fatty acid supplementation on the vascular structure and function in hypertensive patients with hypertriglyceridemia.

Detailed description

Hypertensive patients aged 40-65 years, both genders, presenting serum triglycerides levels higher than 150 mg/dl will be randomized into two groups. The first group will be receiving ciprofibrate 100mg/day and the second group will be receiving fish oil 1800mg/day. All patients will be evaluated with brachial flow-mediated dilation and with EndoPAT to assess endothelial function before and after supplementation. SPHYGMOCOR and pulse wave velocity (PWV) measurements will also be obtained.

Interventions

DIETARY_SUPPLEMENTDHA-EPA

1800 mg/day

DRUGCiprofibrate

100 mg/day

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Previous diagnosis of hypertension * Patients with serum triglycerides levels ≥ 150 mg/dl and \<500 mg/dl * Patients on stable antihypertensive medication for at least 4 weeks * Patients with food consumption maintained for at least 4 weeks

Exclusion criteria

* Smoking * Secondary hypertension * Hormone replacement therapy * Diabetes mellitus * Chronic kidney disease * Known coronary artery disease * Previous stroke * Dyslipidemia severe, with LDL cholesterol\> 160 mg/dL or triglycerides ≥ 500 mg/dl * Use of statins or beta blockers

Design outcomes

Primary

Measure	Time frame	Description
Endothelial function	3 months	Endothelial function evaluated by brachial flow-mediated dilation and by peripheral arterial tonometry.

Countries

Brazil

Contacts

Primary ContactMarcela A. Casanova, MSc

cela.abreu@gmail.com55-21-2868-8484

Backup ContactMario F. Neves, MD, PhD

mariofneves@gmail.com55-21-2868-8485

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026